You are here: Industry Insights > Lonza

News List

Lonza Integrates New Serialization Security Capabilities contractpharma
December 19, 2017
Counterfeit and diverted medicines are a growing threat to patients
Lonza Expands Support for Researchers with New Endothelial Cell Application Center americanpharmaceuticalreview
August 16, 2017
Lonza announced an endothelial cell application center, which expands Lonza’s support for researchers. Increasing our understanding of endothelial cells could help researchers to develop more effective drugs to treat these diseases.
Endothelial cell application centre expands support for researchers europeanpharmaceuticalreview
August 16, 2017
Lonza has announced an endothelial cell application centre, which expands support for researchers…
Lonza starts construction of Biological Development and Manufacturing Complex biospectrumasia
August 02, 2017
bex Solutions include highly flexible models to match and adapt to each customer’s expectations and forecasts. The availability of a modular complex means time-to-market can be reduced by 12 months or more.
Lonza Pharma & Biotech Launches Ibex Solutions contractpharma
August 01, 2017
Represents an innovative new concept in biological manufacturing and development
Lonza completes acquisition of Capsugel cphi-online
July 10, 2017
Acquisition create leading integrated solutions provider to the global pharma and consumer healthcare industries.
Lonza Acquires PharmaCell contractpharma
June 07, 2017
Offers core expertise in autologous cell and gene therapy manufacturing
3rd global endotoxin testing summit pharmaasia
April 10, 2017
The 3rd annual Global Endotoxin Testing Summit brings together discussion on current issues within the endotoxin detection industry.
Lonza expands airway disease portfolio with addition of IPF airway cells pharmaasia
March 15, 2017
Lonza offers cryopreserved lung fibroblasts isolated from donors diagnosed with Idiopathic Pulmonary Fibrosis for use in research into this potentially fatal condition
Sanofi and Lonza to build €270m mammalian cell culture facility in Switzerland pharmaceutical-technology
March 01, 2017
Sanofi and Lonza have plans to invest €270m in a new mammalian cell culture facility in Visp, Switzerland, for monoclonal antibody production.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page